Amphastar PharmaceuticalsAMPH
About: Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
Employees: 1,761
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
248% more call options, than puts
Call options by funds: $3.91M | Put options by funds: $1.12M
50% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 3 (+1) [Q3]
31% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 32
22% more capital invested
Capital invested by funds: $1.4B [Q2] → $1.72B (+$313M) [Q3]
3% more funds holding
Funds holding: 267 [Q2] → 275 (+8) [Q3]
1.01% more ownership
Funds ownership: 71.74% [Q2] → 72.75% (+1.01%) [Q3]
4% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 93
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Wells Fargo Joe Quatrochi 43% 1-year accuracy 3 / 7 met price target | 43%upside $55 | Overweight Initiated | 22 Nov 2024 |
Financial journalist opinion
Based on 4 articles about AMPH published over the past 30 days
